FindTrial
Sign In

Benefits and safety of major medicines in HIV patients.

Study of the efficacy and safety of Dolutegravir based first line anti-retroviral Therapy in people living with HIV infection. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065522
Enrollment
1000
Registered
2024-04-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Institute of Medical Sciences, Banaras Hindu University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Minimum 1000 patients for retrospective and prospective studies with confirmed and documented HIV1 infection on Dolutegravir, Lamivudine and Tenofovir Alafenamide

Exclusion criteria

Exclusion criteria: Patients on 2nd, 3rd, other regimens and patients not giving consent to the study

Design outcomes

Primary

MeasureTime frame
To determine whether a statistically significant reduction in viral load and a statistically significant increase in CD4 cell count happens when compared with the previous regimenTimepoint: Both viral load and CD4 count measured at 6 and 12 months after starting the regimen—

Secondary

MeasureTime frame
To determine statistically significant adverse events once the treatment is startedTimepoint: Follow up at 6 months & 1 year—

Countries

India

Contacts

Public ContactVed Prakash

Institute of Medical Sciences, B.H.U.

sonivedgmc@gmail.com8601741409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026